Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Buisseret, L., Loirat, D., Aftimos, P., Maurer, C., Punie, K., Debien, V., Kristanto, P., Eiger, D., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., Van den Mooter, T., Ferrero, J.-M., Bonnefoi, H., Canon, J.-L., Duhoux, F., Mansi, L., Poncin, R., et al. (2023). Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nature Communications, 14(1), 8223. https://doi.org/10.1038/s41467-023-44071-8 (Original work published 2023)